

**Annual Investigators meeting:
2016 ADC Meeting
Baltimore, MD
October 15, 2016**

NIA Division of Neuroscience- UPDATE

Eliezer Masliah, M.D.
Director, Division of Neuroscience,
National Institute on Aging, NIH

NATIONAL INSTITUTES OF HEALTH

National Institute on Aging

Office of the Director
Richard J. Hodes, M.D.
Marie A. Bernard, M.D.

Intramural Research Program
Luigi Ferrucci, M.D., Ph.D.
Michele K. Evans, M.D.

Division of Extramural Activities
Robin Barr, D.Phil.
Chyren Hunter, Ph.D.

EXTRAMURAL RESEARCH PROGRAMS

Division of Aging Biology
Felipe Sierra, Ph.D.
Ronald Kohanski, Ph.D.


Division of Behavioral and Social Research
John Haaga, Ph.D.
Georgianne Patmios, M.A.

Division of Neuroscience
Eliezer Masliah, M.D.
Creighton Phelps, Ph.D.

Division of Geriatrics and Clinical Gerontology
Evan Hadley, M.D.
Winifred K. Rossi, M.A.

Understanding the aging nervous system and as an *area of focus Alzheimer's disease.*

NIA Division of Neuroscience



* Attending the meeting


Budget changes over the years



National Alzheimer's Project Act (NAPA) signed in 2011

To prevent the onset of and develop effective treatments for AD by 2025.

NIA Appropriations



ADC's	MOVE2
NCRAD	AMP-AD
ADNI	ADSP
ADCS	NACC



National Institute on Aging

FY16 Alzheimer's Disease FOA's



1. **Caregiving**- Basic and Clinical Research on Caregiving for Alzheimer's Disease at the individual, family and community: [PAR-15-348, 351](#).
 2. **Health Disparities**- Studies of behavior, biological and social factors that influence health differences and Alzheimer's Disease: [PAR-15-349, 350](#).
 3. **Epidemiology**- Major Opportunities for Research in Epidemiology of Alzheimer's Disease and Cognitive Resilience: [PAR-15-356](#).
 4. **Brain Aging**- Understanding Alzheimer's Disease in the context of the Aging Brain: [PAR-15-357](#).
 5. **Molecular and Cellular Mechanisms**- Capturing Complexity in the Molecular and Cellular Mechanisms Involved in the Etiology of Alzheimer's Disease: [PAR-15-358](#).
 6. **Diagnosis and Prediction**- Novel Approaches to Diagnosing Alzheimer's Disease & Predicting Progression: [PAR-15-359](#).
 7. **Clinical Trials**- Phase III Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline: [PAR-16-364](#). Pilot Clinical Trials for the Spectrum of Alzheimer's Disease and Age-Related Cognitive Decline: [PAR-16-365](#).
- +3 NINDS initiatives**- AD Related dementias (Lewy body dementia, FTD and vascular).

FY16 Distribution of new funds



Q1


Aging/cognition
sensory

Q2-3

Translation/
preclinical

Clinical research/
clinical trials

Q4




Trans-NIA → DAB, DBSR, DCGC

Trans-NIH → NINDS, NINR, others

AD grants awarded by mechanism FY16

Row Labels	Count of Project
R01	149
RF1	70
R21	61
U01	21
R44	16
R43	15
R56	14
F31	13
P50	9
K99	8
K01	7
R41	6
F32	5
F30	5
U19	5
UF1	5
R03	5
K23	4
K24	4
P01	4
R42	4
R13	4
R37	3
U24	3
K76	3
K25	2
U54	2
R15	2
P30	2
T32	2
R36	1
K08	1
Grand Total	455

AD Awarded in FY16 for DN by Mechanism



Congratulations!

Update 2016

- Two new ADCC's funded- *Michigan (H. Paulson) and Wake Forest (S. Craft)*
- U54 Translational animal models- *IU (B. Lamb), Jackson Lab (G. Howell), Sage Bionetworks (L. Omberg)*
- ADNI3 renewed- *UCSF (M. Weiner), 57 centers, 21 partners*
- NCRAD renewed- *UI (T. Foroud)*
- New AD Genome Center- *U. Penn (J. Schellenberg; L. San)*
- New natural history/epidemiology studies- *(eg: air pollution (WHS); race/ethnic disparities (WHICAP offspring); brain metallomics and neuropathology (Rush MAP); dietary patterns and Vitamin D/Vitamin K links (Rush MAP); mid-life cardiovascular links (ARIC/MESA add-ons); and resilience (Nun Study, HAAS).*
- New Clinical trials- *(eg: F. Longo NTF-like, A. Lim sleep Abeta, CART J. Kaye)*
- Review of AD Centers- *S. Greenberg and 19 others*
- Review Diagnostic Criteria (NIA-AA workgroup)- *C. Jack, C. Phelps, M. Carrillo, 16 others.*
- *AD Summit planned for March 2018**
- *National Plan for FY17 and Bypass budget submitted to Congress*
- **10** FOA's for FY16, **7** **NEW! FOA's for FY17,** **+26** new coming!



2017 Alzheimer's Disease Initiatives




1. **Alzheimer's Clinical Trials** Consortium (ACTC) (U24): <http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-17-005.html>.
2. **From Association to Function** in the Alzheimer's Disease Post Genomics Era (R21, R01) <http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-17-10,11.html>
3. Phenotypic and **Functional Characterization of ApoE2** to Inform Translation Strategies for Aging-Related Conditions (R01): <http://grants.nih.gov/grants/guide/pa-files/PA-16-370.html>;
4. Impact of **Aging in Human Cell Models** of Alzheimer's Disease (R01): <http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-17-009.html>
5. Inclusion of **Mobile/e-Consents** for AD Research: <http://grants.nih.gov/grants/guide/pa-files/PA-16-259.html>
6. Aging Research to Address **Health Disparities**: <http://grants.nih.gov/grants/guide/pa-files/PA-16-225.html>
7. Small Business Alzheimer's Disease Research – Technology Transfer (**STTR**) (R41/42): <http://grants.nih.gov/grants/guide/pa-files/PA-16-092.html>; Innovation Research (**SBIR**) (R43/44): <http://grants.nih.gov/grants/guide/pa-files/PA-16-091.html>.

K awards, training grants, fellowship awards

FY16 Budget Status – Funding Increases Across the Board

**\$32
Billion for
the NIH**



- **FY17 Draft Appropriations bills also include additional NIH funds for AD**
- **Senate -- \$400M**
- **House -- \$350M**

- **\$1.6B for the NIA**
- **~4 percent increases across all ICs (not counting the \$\$ above) – 4.2% for the NIA**
- **All divisions will benefit**
 - DBSR
 - DAB
 - DGCG
 - DN

26+ New Trans-NIA Initiatives

- **Trans-NIA (DAB, DBR, DGCG, DEA)**
- **11 from DN**
- **New drug development programs**
- **Training programs**
- **Basic mechanisms of disease**
- **New centers**
- **More resources and tools**
- **SBIR/STTR's**

- *Additional FOA's from NINDS*



Inside NIA: A Blog for Researchers




Preparing for a possible future: Advancing research into Alzheimer's disease

Posted on October 12, 2016 by Richard Hodes, Director, National

Program integration toward achieving the 2025 goal of NAPA (from discovery to the clinic)

Think about how your **ADC** could further participate in becoming a part of the program super-structure and the long term goal



To prevent the onset and develop effective treatments for AD by 2025

S. Petanceska



Dale Scheck
1957-2016

THANKS